Compare PED & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | BDSX |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Precision Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | PED | BDSX |
|---|---|---|
| Price | $0.56 | $7.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $1.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 152.6K | 57.5K |
| Earning Date | 11-17-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $33,244,999.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | $305.89 | $25.05 |
| P/E Ratio | $5.37 | ★ N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.43 | $3.44 |
| 52 Week High | $1.00 | $32.20 |
| Indicator | PED | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 54.81 | 51.69 |
| Support Level | $0.43 | $7.68 |
| Resistance Level | $0.55 | $8.17 |
| Average True Range (ATR) | 0.04 | 0.66 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 83.57 | 55.68 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.